Robert A. Gross, MD, PhD, FAAN, Editor-in-Chief, *Neurology*®

Notable in *Neurology* this week

This issue features an article that explains the clinical value of the central vein sign on a clinical 3T scanner for the differential diagnosis of multiple sclerosis and neuromyelitis optica spectrum disorder; another details the suitability of atrophy, demyelination, and iron accumulation as markers of therapeutic intervention following spinal cord injury. A featured Special Article outlines the American Academy of Neurology Institute and Society for Neuro-Oncology approved quality measurement set for neuro-oncology.

Articles

Sun exposure over the life course and associations with multiple sclerosis

Sunlight exposure may alter multiple sclerosis (MS) risk; however, its measurement and timing are not well-delineated. The authors reviewed sun exposure in patients with MS and age-matched controls, and found that living in high (vs low) ultraviolet B areas prior to MS onset was associated with a lower MS risk.

Page 638

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

As cannabidiol use increases among patients with epilepsy, pharmacokinetic data are needed. In this study of children with Dravet syndrome, cannabidiol levels and levels of its metabolites increased proportionally with dose. The only antiepileptic drug interaction was an increase in the nordesmethyl metabolite of clobazam. These findings emphasize a need for more cannabidiol data.

Page 640

Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy

In this article, the authors elucidate a potential new therapy for an underdiagnosed and disabling genetic condition: primary mitochondrial myopathy (PMM). Elamipretide, studied in PMM, improved exercise performance following 5 days of IV treatment without safety concerns. Elamipretide's therapeutic benefits support initiation of a phase 3 program in patients with PMM.

Page 641

From editorialists Vissing and Angelini: "Remodeling the mitochondrial inner membrane with elamipretide is an interesting new treatment strategy for mitochondrial myopathies, which although not curative, could prove an important treatment option for this patient group, not only as monotherapy, but potentially also in combination with aerobic training or other noncurative therapies."

Page 633

MORE ONLINE

Editor's Summary

Audio summary of highlighted articles.

NPub.org/edsum

Continued

Arterial stiffness and dementia pathology: Atherosclerosis Risk in Communities (ARIC)-PET Study

Arterial stiffness is underappreciated as a biomarker of dementia risk. The authors show, in a cross-sectional study, that greater arterial stiffness is associated with evidence of dementia pathology seen on MRI and PET. The effects of hemodynamic abnormalities in the pathologic progression of dementia are just beginning to emerge.

Page 645

From editorialists Lopez and Maillard: "These findings confirmed previous observations on the relationship between arterial stiffness and A β amyloid deposition, and consolidated the notion that there is an association between systemic vascular disease and A β amyloid deposition."

Page 635

NB: "International Issues: A guide to US academic global health programs in neurology," p. 662. To check out other Resident & Fellow International Issues articles, point your browser to Neurology.org/N and click on the link to the Resident & Fellow section. At the end of the issue, check out the Resident & Fellow Clinical Reasoning paper discussing the case of a middle-aged woman presenting with headache and an altered mental status. This week also includes a Video NeuroImage titled "Paraneoplastic spinal myoclonus associated with Caspr2 antibodies."

NEW EPISODE

April 3, 2018

The mitochondrial disease patients' diagnostic odyssey: Results of a survey (see the April 2018 issue of *Neurology® Genetics*)

1. Featured Article: The mitochondrial disease patients' diagnostic odyssey: Results of a survey
2. What's Trending: Teen concussion and early tauopathy

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 3, 2018, issue of *Neurology*. In the first segment, Dr. Jason Crowell talks with Drs. John L.P. Thompson and Michio Hirano about their *Neurology: Genetics* paper on the long journey to diagnosis for patients with mitochondrial disease. For the "What's Trending" segment, Dr. Jeff Ratliff speaks with Dr. Lee Goldstein about teen concussion and early tauopathy.

Disclosures can be found at Neurology.org/podcast.

No CME this week: Interviews based on articles from *Neurology® Clinical Practice*, *Neurology: Genetics*, and *Neurology® Neuroimmunology & Neuroinflammation* are excluded from the CME program.

Neurology[®]

Spotlight on the April 3 issue

Robert A. Gross

Neurology 2018;90;629-630

DOI 10.1212/WNL.0000000000005244

This information is current as of April 2, 2018

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/90/14/629.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.